Jefferies Financial Group set a €68.00 ($79.07) price objective on Fresenius Medical Care AG & Co. KGaA (ETR:FME) in a report published on Friday, June 28th, Borsen Zeitung reports. The firm currently has a neutral rating on the stock.
A number of other equities research analysts have also issued reports on FME. Berenberg Bank reduced their target price on from GBX 4,600 ($60.11) to GBX 3,800 ($49.65) and set a hold rating on the stock in a research note on Friday, June 28th. UBS Group set a €83.00 ($96.51) target price on Schneider Electric and gave the company a buy rating in a research note on Thursday, June 27th. Morgan Stanley reaffirmed an overweight rating and issued a C$125.00 target price on shares of Intact Financial in a research note on Wednesday, May 15th. JPMorgan Chase & Co. set a €56.70 ($65.93) target price on Fresenius SE & Co KGaA and gave the company a buy rating in a research note on Monday, June 24th. Finally, Barclays reaffirmed a hold rating and issued a $14.00 target price on shares of MACOM Technology Solutions in a research note on Thursday, June 20th. Seven equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Fresenius Medical Care AG & Co. KGaA presently has an average rating of Buy and a consensus target price of €82.57 ($96.01).
Shares of FME traded down €0.74 ($0.86) on Friday, reaching €67.00 ($77.91). The stock had a trading volume of 805,829 shares, compared to its average volume of 704,197. The stock has a market cap of $20.45 billion and a price-to-earnings ratio of 10.43. The company has a debt-to-equity ratio of 100.05, a current ratio of 1.02 and a quick ratio of 0.67. The company’s 50-day moving average is €68.38. Fresenius Medical Care AG & Co. KGaA has a twelve month low of €55.44 ($64.47) and a twelve month high of €91.74 ($106.67).
Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Featured Story: Understanding Market Liquidity
Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.